Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 2/2013

01-04-2013 | RESPIRATORY INFECTIONS (F ARNOLD, SECTION EDITOR)

Hospital Admission Decision for Patients with Community-Acquired Pneumonia

Authors: Stefano Aliberti, Paola Faverio, Francesco Blasi

Published in: Current Infectious Disease Reports | Issue 2/2013

Login to get access

Abstract

Where to treat patients is probably the single most important decision in the management of community-acquired pneumonia (CAP), with a substantial impact on both patients’ outcomes and health-care costs. Several factors can contribute to the decision of the site of care for CAP patients, including physicians’ experience and clinical judgment and severity scores developed to predict mortality, as well as social and health-care-related issues. The recognition, both in the community and in the emergency department, of the presence of severe sepsis and acute respiratory failure and the coexistence with unstable comorbidities other than CAP are indications for hospital admission. In all the other cases, physician’s choice to admit CAP patients should be validated against at least one objective tool of risk assessment, with a clear understanding of each score’s limitations.
Literature
1.
Raut M, Schein J, Mody S, et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin. 2009;25:2151–7.PubMedCrossRef
2.
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27–72.PubMedCrossRef
3.
Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17 Suppl 6:E1–59.PubMedCrossRef
4.
Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1–55.PubMedCrossRef
5.
Chalmers JD, Taylor J, Mandal P, et al. Validation of the IDSA/ATS minor criteria for ICU admission in communityacquired pneumonia patients without major criteria or contraindications to ICU care. Clin Infect Dis. 2011;53:107–13.PubMedCrossRef
6.
Phua J, See KC, Chan YH, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe communityacquired pneumonia. Thorax. 2009;64:598–603.PubMedCrossRef
7.
Rello J, Rodriguez A, Lisboa T, et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009;37:456–62.PubMedCrossRef
8.
Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375–84.PubMedCrossRef
9.
Kohno S, Seki M, Watanabe A. Evaluation of an assessment system for the JRS 2005: A-DROP for the management of CAP in adults. Intern Med. 2011;50:1183–91.PubMedCrossRef
10.
Buising KL, Thursky KA, Black JF, et al. Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas. 2007;19:418–26.PubMedCrossRef
11.
Renaud B, Labarere J, Coma E, et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care. 2009;13:R54.PubMedCrossRef
12.
Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe communityacquired pneumonia. Am J Respir Crit Care Med. 2006;174:1249–56.PubMedCrossRef
13.
Yandiola PP, Capelastegui A, Quintana J, et al. Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest. 2009;135:1572–9.PubMedCrossRef
14.
Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37:1409–20.PubMedCrossRef
15.
Jin Y, Marrie TJ, Carriere KC, et al. Variation in management of community-acquired pneumonia requiring admission to Alberta. Canada hospitals. Epidemiol Infect. 2003;130:41–5.PubMedCrossRef
16.
Dean NC, Jones JP, Aronsky D, et al. Hospital admission decision for patients with community-acquired pneumonia: variability among physicians in an emergency department. Ann Emerg Med. 2012;59:35–41.PubMedCrossRef
17.
Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 1997;157:36–44.PubMedCrossRef
18.
Barlow G, Nathwani D, Myers E, et al. Identifying barriers to the rapid administration appropriate antibiotics in communityacquired pneumonia. J Antimicrob Chemother. 2008;61:442–51.PubMedCrossRef
19.
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.PubMedCrossRef
20.
Woodhead M. Assessment of illness severity in community acquired pneumonia: a useful new prediction tool? Thorax. 2003;58:371–2.PubMedCrossRef
21.
Arnold F, LaJoie A, Marrie T, et al. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. Int J Tuberc Lung Dis. 2006;10:739–43.PubMed
22.
Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.PubMedCrossRef
23.
Capelastegui A, España PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006;27:151–7.PubMedCrossRef
24.
Bauer TT, Ewig S, Marre R, et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260:93–101.PubMedCrossRef
25.
•• Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65(10):878–83. This is a recent systematic review and meta-analysis of 40 studies focused on prognostic information of PSI, CURB-65, and CRB-65 and showing no significant differences in overall test performance among the three scores for predicting mortality from community-acquired pneumonia.PubMedCrossRef
26.
Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax. 2010;65:884–90.PubMedCrossRef
27.
Arnold FW, Wiemken T, Peyrani P, et al. Outcomes in females hospitalised with community-acquired pneumonia are worse than males. Eur Respir J. 2012 Jul 26. [Epub ahead of print]
28.
Parsonage M, Nathwani D, Davey P, Barlow G. Evaluation of the performance of CURB-65 with increasing age. Clin Microbiol Infect. 2009;15:858–64.PubMedCrossRef
29.
Myint PK, Kamath AV, Vowler SL, et al. The CURB (confusion, urea, respiratory rate and blood pressure) criteria in community-acquired pneumonia (CAP) in hospitalised elderly patients aged 65 years and over: a prospective observational cohort study. Age Ageing. 2005;34:75–7.PubMedCrossRef
30.
Chen JH, Chang SS, Liu JJ, et al. Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects. Thorax. 2010;65:971–7.PubMedCrossRef
31.
Heppner HJ, Sehlhoff B, Niklaus D, et al. Pneumonia Severity Index (PSI), CURB-65, and mortality in hospitalized elderly patients with aspiration pneumonia. Z Gerontol Geriatr. 2011;44:229–34.PubMedCrossRef
32.
Fang WF, Yang KY, Wu CL, et al. Application and comparison of severity indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care. 2011;15:R32.PubMedCrossRef
33.
Falcone M, Corrao S, Venditti M, et al. Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia. Intern Emerg Med. 2011;6:431–6.PubMedCrossRef
34.
Mulrennan S, Tempone SS, Ling IT, et al. Pandemic influenza (H1N1) 2009 pneumonia: CURB-65 score for predicting severity and nasopharyngeal sampling for diagnosis are unreliable. PLoS One. 2010;5:e12849.PubMedCrossRef
35.
Bjarnason A, Thorleifsdottir G, Löve A, et al. Severity of Influenza A 2009 (H1N1) pneumonia is underestimated by routine prediction rules. Results from a prospective, population-based study. PLoS One. 2012;7:e46816.PubMedCrossRef
36.
Myles PR, Nguyen-Van-Tam JS, Lim WS, et al. Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. PLoS One. 2012;7:e34428.PubMedCrossRef
37.
Commons RJ, Denholm J. Triaging pandemic flu: pneumonia severity scores are not the answer. Int J Tuberc Lung Dis. 2012;16:670–3.PubMed
38.
Pereira JM, Moreno RP, Matos R, et al. Severity assessment tools in ICU patients with 2009 Influenza A (H1N1) pneumonia. Clin Microbiol Infect. 2012;18:1040–8.PubMedCrossRef
39.
Aliberti S, Brock GN, Peyrani P, et al. The pneumonia severity index and the CRB-65 in cancer patients with community-acquired pneumonia. Int J Tuberc Lung Dis. 2009;13:1550–6.PubMed
40.
Asai N, Motojima S, Ohkuni Y, et al. Non-HIV Pneumocystis pneumonia: do conventional community-acquired pneumonia guidelines under estimate its severity? Multidiscip Respir Med. 2012;11(7):2.CrossRef
41.
Nathwani D, Morgan M, Masterton RG, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother. 2008;61:976–94.PubMedCrossRef
42.
Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64:587–91.PubMedCrossRef
43.
Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31:349–55.PubMedCrossRef
44.
Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008;52:48–58.PubMedCrossRef
45.
Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community acquired pneumonia. Chest. 2009;136:823–31.PubMedCrossRef
46.
• Krüger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short- and longterm survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010;182:1426–34. In this study, performed on more than 700 patients with CAP, the authors showed proadrenomedullin, proatrial natriuretic peptide, and copeptin to be good predictors of short- and long-term all-cause mortality, superior to inflammatory markers and at least comparable to CRB-65 score.PubMedCrossRef
47.
Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med. 2012. doi:10.​1016/​j.​ajem.​2012.​07.​017.
48.
Albrich WC, Dusemund F, Rüegger K, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis. 2011;3(11):112.CrossRef
49.
Krüger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med. 2007;33:2069–78.PubMedCrossRef
50.
Kolditz M, Höffken G, Martus P, et al. Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis. 2012;13(12):90.CrossRef
51.
Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;176:913–20.PubMedCrossRef
52.
Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia.CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283:749–55.PubMedCrossRef
53.
Carratala J, Fernandez-Sabe N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med. 2005;142:165–72.PubMed
54.
Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized controlled trial. Ann Intern Med. 2005;143:881–94.PubMed
55.
Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med. 1998;158:1350–6.PubMedCrossRef
56.
Renaud B, Coma E, Labarere J, et al. Routine use of the pneumonia severity index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis. 2007;44:41–9.PubMedCrossRef
57.
Jo S, Kim K, Jung K, et al. The effects of incorporating a pneumonia severity index into the admission protocol for community-acquired pneumonia. J Emerg Med 2010 [epub ahead of print].
58.
Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J. 2011;37:858–64.PubMedCrossRef
59.
Seymann G, Barger K, Choo S, et al. Clinical judgment versus the Pneumonia Severity Index in making the admission decision. J Emerg Med. 2008;34:261–8.PubMedCrossRef
60.
Marrie TJ, Huang JQ. Low-risk patients admitted with community-acquired pneumonia. Am J Med. 2005;118:1357–63.PubMedCrossRef
61.
Arnold FW, Ramirez JA, McDonald LC, Xia EL. Hospitalization for communityacquired pneumonia: the pneumonia severity index vs clinical judgement. Chest. 2003;124:121–4.PubMedCrossRef
62.
Chan SS. The Pneumonia Severity Index as a decision-making tool to guide patient disposition. Am J Emerg Med. 2002;20:387–8.PubMedCrossRef
63.
Ewig S, de Roux A, Garcia E, et al. Validation of predictive rules and indices of severity for community-acquired pneumonia. Thorax. 2004;59:421–7.PubMedCrossRef
64.
Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest. 2003;124:2148–55.PubMedCrossRef
65.
Marras TK, Gutierrez C, Chan CK. Applying a prediction rule to iden tify low-risk patients with community-acquired pneumonia. Chest. 2000;118:1339–43.PubMedCrossRef
66.
Espana PP, Capelastegui A, Quintana JM, et al. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J. 2003;21:695–701.PubMedCrossRef
67.
• Aujesky D, McCausland JB, Whittle J, et al. Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. Clin Infect Dis. 2009;49(10):e100–8. This trial enrolling more than 1,300 patients showed that emergency medicine physicians tend to hospitalize many low-risk patients with CAP, most frequently for a comorbid illness.PubMedCrossRef
68.
Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J. 2007;14:212–6.PubMed
69.
Singanayagam A, Wood V, Chalmers JD. Factors associated with severe illness in Pandemic 2009 influenza A (H1N1) infection: implications for triage in primary and secondary care. J Infect. 2011;63:243–51.PubMedCrossRef
70.
Riquelme R, Jimenez P, Videla AJ, et al. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. Int J Tuberc Lung Dis. 2011;15:542–6.PubMedCrossRef
71.
McCartney C, Cookson B, Dance D. Interim guidance on diagnosis and management of Panton–Valentine leukocidin-associated staphylococcal infections in the UK. London: Department of Health; 2006.
72.
Aliberti S, Ramirez J, Cosentini R, et al. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respir Med. 2011;105:1732–8.PubMedCrossRef
73.
Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011;38:643–8.PubMedCrossRef
74.
Sanz F, Restrepo MI, Fernández E, et al. Hypoxemia adds to the CURB-65 pneumonia severity score in hospitalized patients with mild pneumonia. Respir Care. 2011;56:612–8.PubMedCrossRef
75.
•• Kolditz M, Ewig S, Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2012, Sep 27. [Epub ahead of print]. This paper gives a very interesting perspective on site-of-care decision in patients with community-acquired pneumonia. An integration between a physiopathological approach and severity scores is discussed, and a possible role of biomarkers is proposed.
76.
Lee RW, Lindstrom ST. A teaching hospital's experience applying the Pneumonia Severity index and antibiotic guidelines in the management of communityacquired pneumonia. Respirology. 2007;12:754–8.PubMedCrossRef
77.
Nadarajan P, Wilson L, Mohammed B, et al. Compliance in the measurement of CURB-65 in patients with community-acquired pneumonia and potential implications for early discharge. Ir Med J. 2008;101:144–6.PubMed
78.
Karmakar G, Wilsher M. Use of the 'CURB 65' score in hospital practice. Intern Med J. 2010;40:828–32.PubMedCrossRef
79.
80.
Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM. 2011;104:871–9.PubMedCrossRef
81.
Bont J, Hak E, Hoes AW, et al. Predicting death in elderly patients with community-acquired pneumonia: a prospective validation study re-evaluating the CRB65 severity assessment tool. Arch Intern Med. 2008;168:1465–8.PubMedCrossRef
82.
McNally M, Curtain J, O'Brien KK, et al. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract. 2010;60(579):e423–33.PubMedCrossRef
83.
Francis NA, Cals JW, Butler CC, et al. Severity assessment for lower respiratory tract infections: potential use and validity of the CRB-65 in primary care. Prim Care Respir J. 2012;21:65–70.PubMedCrossRef
84.
Silber SH, Garrett C, Singh R, et al. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest. 2003;124:1798–804.PubMedCrossRef
85.
Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012;54:470–8.PubMedCrossRef
86.
Aliberti S, Peyrani P, Filardo G, et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest. 2011;140:482–8.PubMedCrossRef
87.
Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008;134:955–62.PubMedCrossRef
Metadata
Title
Hospital Admission Decision for Patients with Community-Acquired Pneumonia
Authors
Stefano Aliberti
Paola Faverio
Francesco Blasi
Publication date
01-04-2013
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 2/2013
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-013-0323-7

Other articles of this Issue 2/2013

Current Infectious Disease Reports 2/2013 Go to the issue

RESPIRATORY INFECTIONS (F ARNOLD, SECTION EDITOR)

Is Prolonged Low-Dose Glucocorticoid Treatment Beneficial in Community-Acquired Pneumonia?

RESPIRATORY INFECTIONS (F ARNOLD, SECTION EDITOR)

Epidemiologic and Clinical Implications of Second-Generation Pneumococcal Conjugate Vaccines

Genitourinary Infections (J Sobel, Section Editor)

Treatment of Complicated Urinary Tract Infections With an Emphasis on Drug-Resistant Gram-Negative Uropathogens

RESPIRATORY INFECTIONS (F ARNOLD, SECTION EDITOR)

Does an Upper Respiratory Tract Infection During Pregnancy Affect Perinatal Outcomes? A Literature Review

RESPIRATORY INFECTIONS (F ARNOLD, SECTION EDITOR)

Determining the Duration of Therapy for Patients with Community-Acquired Pneumonia

GENITOURINARY INFECTIONS (J SOBEL, SECTION EDITOR)

Alternative Approaches to Conventional Treatment of Acute Uncomplicated Urinary Tract Infection in Women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits